SAT-215 Prediction models for response to growth hormone treatment in children with short stature analysis of data from LGS

Abstract Disclosure: S. Kim: None. S. Kim: None. S. Kim: None. M. Ahn: None. W. Cho: None. K. Cho: None. M. Jung: None. B. Suh: None. Background: The aim of this study was to predict responsiveness to growth hormone (GH) treatment and to propose a prediction model for height outcomes in growth disorders during the first three years of therapy. Methods: A total of 2,463 pediatric patients with short stature (I-GHD, ISS, and SGA) from the LG Growth Study cohort were evaluated. Multiple regression analyses were performed to develop prediction models for the treatment period. The final model was selected using the Mallow's C(p) criterion. Results: The prediction models, which included variables such as age, bone age, initial height SDS, weight SDS, height SDS minus mid-parental height SDS, GH dose, peak GH level, and prior year ΔHeight SDS, explained 14.7%, 45.2%, and 29% of the variability in height SDS changes during the first, second, and third years of treatment, respectively, in subjects with GHD. For subjects with ISS, the models explained 12.5%, 26.6%, and 21.7% of the variability in the height SDS changes during the corresponding treatment periods. In subjects with SGA, the models explained 38.9% and 47.6% of the variability in height SDS changes during the second and third year of treatment, respectively. Conclusions: The model predicted the first- to third-year response to GH treatment, facilitating personalized therapy for Korean children with I-GHD, ISS, and SGA. Multiple linear regression analyses revealed that the change in height SDS from the previous year was the key factor influencing the height response. Presentation: Saturday, July 12, 2025